Document Detail

Adverse drug events associated with yohimbine-containing products: a retrospective review of the California Poison Control System reported cases.
MedLine Citation:
PMID:  20442348     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Herbal supplements are classified as foods rather than drugs and are not required to undergo premarketing review by the Food and Drug Administration. Yohimbine is an alpha(2)-antagonist available in both prescription and herbal supplement products.
OBJECTIVE: To determine the prevalence and severity of yohimbine-related adverse drug events (ADEs) reported to the California Poison Control System (CPCS).
METHODS: A retrospective review of the CPCS electronic database of cases within a 7-year period (2000-2006) was conducted. Cases involving adults aged 18 and older who were symptomatic following exposure to a yohimbine-containing product, with a causality rating of possible or better on the Naranjo scale, were included.
RESULTS: A total of 238 cases were identified. There was a substantial increase in the annual prevalence of yohimbine-associated ADEs reported to the CPCS between 2000 and 2006; specifically, the prevalence (per 10,000 total adult exposures) increased from 1.8 cases in 2000 to 8.0 cases in 2006). The majority (98.7%) of cases involved herbal (vs prescription) yohimbine products. Common reasons for use included sexual enhancement (27.7%), weight loss (9.2%), and stimulant effects (7.6%). Common ADEs reported included: gastrointestinal distress (46%), tachycardia (43%), anxiety/agitation (33%), and hypertension (25%). Yohimbine exposures were associated with a significantly greater proportion of severe outcomes and were more likely to require management at a health-care facility than the average substance exposure reported to the CPCS (odds ratios [95% CIs] were 5.81 [4.43 to 7.64] and 2.35 [1.82 to 3.04], respectively).
CONCLUSIONS: A substantial increase in the prevalence of ADEs associated with yohimbine herbal products was seen between 2000 and 2006. These ADEs were associated with significantly more serious outcomes than the average exposures reported to the CPCS. A reexamination of whether yohimbine should be considered a "safe" dietary supplement under the Dietary Supplement Health and Education Act is warranted.
Thomas Kearney; Nora Tu; Christine Haller
Related Documents :
636408 - Meningococcal disease in california. epidemiology and management.
1948638 - Tuberculosis increasing in the united states.
20639668 - Streptobacillus moniliformis bacteremia in a child: case report.
8632498 - Outbreak of obstructive ventilatory impairment associated with consumption of sauropus ...
6776828 - Seizures terminable and interminable with ect.
11784418 - Plasmodium vivax relapses after 5 days of primaquine treatment, in some industrial comp...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-05-04
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  44     ISSN:  1542-6270     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-05-21     Completed Date:  2011-01-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1022-9     Citation Subset:  IM    
Managing California Poison Control System, Department of Clinical Pharmacy, School of Pharmacy, University of California at San Francisco, CA 94143, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
California / epidemiology
Databases, Factual / trends
Drug Toxicity / epidemiology*
Middle Aged
Poison Control Centers / trends*
Retrospective Studies
Yohimbine / adverse effects*,  poisoning
Young Adult
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Online health information seeking in the context of the medical consultation in Switzerland.
Next Document:  Problems with medicine packages: experiences reported to a Dutch medicine reporting system.